LeukoSite: Preemptive strike

Last year, LeukoSite Inc. was one of the companies that contributed to the discovery of CCR-5, the chemokine co-receptor used by HIV to enter T cells. Although the finding was outside of LeukoSite's core programs in inflammatory and autoimmune diseases, the work grew out of the company's focus on leukocyte recruitment, the process by which white blood cells are activated, leave the blood stream and enter surrounding tissue.

The company

Read the full 694 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE